Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of
the combination regimen of NK012 and carboplatin in patients with advanced solid tumors.